Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit

Publish date:: November 13, 2020

Key clinical point: Omecamtiv mecarbil safely met its efficacy goal in its pivotal trial in patients with heart failure with reduced ejection fraction.

Major finding: Treatment with omecamtiv mecarbil cut the primary endpoint by a significant 8% relative to placebo.

Study details: GALACTIC-HF enrolled 8,256 patients with HFrEF in an international pivotal trial.

Disclosures: GALACTIC-HF was sponsored by Amgen, Cytokinetics, and Servier, the companies developing omecamtiv mecarbil. Dr. Teerlink has received research support from and been a consultant to Amgen, Cytokinetics, and Servier, as well as Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic, Merck, and Novartis. Dr. Heidenreich had no disclosures. Dr. Mann is on a steering committee for a trial sponsored by Novartis and has no other commercial disclosures. Dr. Lewis is principal investigator for a trial of omecamtiv mecarbil and has no other commercial disclosures.

Citation:

FROM AHA 2020

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Gender surgical outcomes differ following puberty suppression,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Lipid Disorders

Study results support screening rosacea patients for cardiometabolic disease,

Endoscopic intragastric balloon improved NASH parameters,

Obesity phenotyping matches patients with more effective interventions,

Liquid biopsy captures key NASH pathology hallmarks,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,